Kite immunotherapy drug helps blood cancer patients in study
(Reuters) - Kite Pharma Inc on Monday said its experimental CAR T-cell therapy, which helps the immune system fight cancer, was highly effective in treating aggressive non-Hodgkin lymphoma, although two deaths were related to the drug, according to interim data from a midstage trial. (Source: Reuters: Health)
Source: Reuters: Health - September 26, 2016 Category: Consumer Health News Tags: healthNews Source Type: news

AbbVie Announces Submission of a Supplemental New Drug Application for Ibrutinib (IMBRUVICA(R)) for Treatment of Marginal Zone Lymphoma
NORTH CHICAGO, Ill., Sept. 26, 2016 -- (Healthcare Sales & Marketing Network) -- AbbVie (ABBV), a global biopharmaceutical company, today announced that it submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA)... Biopharmaceuticals, Oncology, FDA AbbVie, IMBRUVICA, ibrutinib, non-Hodgkin's lymphoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 26, 2016 Category: Pharmaceuticals Source Type: news

Therapy 'Step Forward' for Non-Hodgkin Lymphoma
Early trial results termed 'fantastic step forward' in fight against non-Hodgkin lymphoma (Source: WebMD Health)
Source: WebMD Health - September 8, 2016 Category: Consumer Health News Source Type: news

Immune Therapy Makes Headway Against a Lymphoma
Early trial results termed'fantastic step forward'in fight against non - Hodgkin lymphoma (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 8, 2016 Category: Cancer & Oncology Authors: webmaster at doctorslounge.com Tags: Oncology, Pharmacy, News, Source Type: news

Immune Therapy Makes Headway Against a Lymphoma
Early trial results termed 'fantastic step forward' in fight against non-Hodgkin lymphoma Source: HealthDay Related MedlinePlus Pages: Cancer Chemotherapy, Lymphoma (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - September 8, 2016 Category: Consumer Health News Source Type: news

Immune Therapy Makes Headway Against a Lymphoma
THURSDAY, Sept. 8, 2016 -- Genetically engineered immune cells appear capable of eradicating non-Hodgkin lymphoma when coupled with effective chemotherapy, a new early trial finds. In this experimental therapy, white blood cells known as T-cells... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 8, 2016 Category: Journals (General) Source Type: news

Patients with advanced lymphoma in remission after T-cell therapy
(Fred Hutchinson Cancer Research Center) In a paper published today in Science Translational Medicine, researchers from Fred Hutchinson Cancer Research Center shared data from an early-phase study of patients with advanced non-Hodgkin lymphoma (NHL) who received JCAR014, a Chimeric Antigen Receptor (CAR) T cell treatment, and chemotherapy. CAR T cells are made from a patient's own immune cells that are then genetically engineered to better identify and kill cancer cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 7, 2016 Category: Cancer & Oncology Source Type: news

CAR-T cell therapy makes strides in clinic *free*
(American Association for the Advancement of Science) In a phase 1 clinical study of 32 participants with advanced B cell non-Hodgkin lymphoma, immunotherapy with defined subsets of T cells, rather than whole T cell populations, showed strong antitumor activity. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 7, 2016 Category: Cancer & Oncology Source Type: news

Patients with advanced lymphoma in remission after T-cell therapy
(Fred Hutchinson Cancer Research Center) In a paper published today in Science Translational Medicine, researchers from Fred Hutchinson Cancer Research Center shared data from an early-phase study of patients with advanced non-Hodgkin lymphoma (NHL) who received JCAR014, a Chimeric Antigen Receptor (CAR) T cell treatment, and chemotherapy. CAR T cells are made from a patient's own immune cells that are then genetically engineered to better identify and kill cancer cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 7, 2016 Category: Cancer & Oncology Source Type: news

Plaintiffs Seek Order From JPMDL Centralizing Roundup Glyphosate Cases
WASHINGTON, D.C. - Some of the plaintiffs in the Roundup Products Liability Litigation pending before the Judicial Panel on Multidistrict Litigation (JPMDL) filed a brief on Aug. 25 calling for the centralization of 26 cases in an MDL in Illinois federal court on grounds that all of the cases allege that exposure to glyphosate resulted in the development of non-Hodgkin's lymphoma (NHL) (In Re: Roundup Products Liability Litigation, No. 2741, JPMDL). (Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News)
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - September 7, 2016 Category: Medical Law Source Type: news

Does Roundup Cause Cancer?
It's one thing for a presidential candidate to support and defend a company that is responsible for genetically engineering organisms (GMOs) that have been banned in 38 countries. But it's quite another for a candidate to defend, invest in, or take hundreds of thousands of dollars from a company whose most successful product is the target of lawsuits that claim it causes cancer. Democratic presidential nominee Hillary Clinton has enjoyed a long, profitable relationship with Monsanto. The St. Louis-based agribusiness giant is a world leader in GMOs. It also manufactures Roundup, the popular weed killer that multiple stud...
Source: Healthy Living - The Huffington Post - September 1, 2016 Category: Consumer Health News Source Type: news

Mesothelioma Clinical Trial for Tazemetostat Launches in US
City of Hope cancer center thoracic oncologist Dr. Marianna Koczywas explains the workings of tazemetostat — the latest drug tested in a mesothelioma clinical trial — with the lock and key metaphor. “You have a specific [cancer] key, and a specific keyhole it goes through. If you can lock that keyhole, you can lock it out,” Koczywas told Asbestos.com. “These malignant cells rely on a pathway for growth and division so you try and block that specific pathway.” Koczywas is principal investigator for the mesothelioma clinical trial at the City of Hope National Medical Center in Los Angeles,...
Source: Asbestos and Mesothelioma News - August 31, 2016 Category: Environmental Health Authors: Walter Pacheco Tags: cancer treatment city of hope cancer center clinical trials at memorial sloan kettering clinical trials in california malignant pleural mesothelioma treatment marianna koczywas mesothelioma clinical trial tazemetostat Source Type: news

Molecular Monitoring of Cell-Free Circulating Tumor DNA in Non-Hodgkin Lymphoma
In this review, we discuss the potential applications of monitoring ctDNA in patients with diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - August 16, 2016 Category: Cancer & Oncology Authors: Christopher Melani, MD Mark Roschewski, MD Tags: Hematologic Malignancies Leukemia & Lymphoma Oncology Journal Review Article Source Type: news

Calif. rancher sues Monsanto claiming four decades of Roundup use caused non-Hodgkin's Lymphoma
(NaturalNews) A California rancher has filed a lawsuit against Monsanto in federal court, accusing the country of misleading customers into believing that the blockbuster herbicide Roundup was as safe as table salt.Plaintiff Peter Johansing says that he used Roundup for 40 years... (Source: NaturalNews.com)
Source: NaturalNews.com - July 20, 2016 Category: Consumer Health News Source Type: news

Non-Hodgkin's Lymphoma
Title: Non-Hodgkin's LymphomaCategory: Diseases and ConditionsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 7/14/2016 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - July 14, 2016 Category: Cancer & Oncology Source Type: news

Nearly 1 in 12 patients with a common cancer develop a second, unrelated malignancy
UCLA researchers have identified the incidence and long-term outcomes of patients who develop second, unrelated cancers, resulting in a data set that they say sheds new light on the way cancer survivors may need to be monitored post-disease. The researchers identified more than 2.1 million patients from the Surveillance, Epidemiology and End Results database, or SEER, with the most common cancers — prostate, breast, lung, colon, rectum, bladder, uterus, kidney and melanoma and non-Hodgkin lymphoma. The team found that 8 percent of patients developed secondary cancers elsewhere, the most common of which was lung cance...
Source: UCLA Newsroom: Health Sciences - July 13, 2016 Category: Universities & Medical Training Source Type: news

Federal judge denies Monsanto's request to toss lawsuit filed by Hawaiian coffee farmer diagnosed with non-Hodgkin's lymphoma
(NaturalNews) The world's most evil corporation was dealt a major legal blow recently, after trying to silence a Hawaiian couple for claiming injury from the use of glyphosate, a highly controversial weedkiller that the World Health Organization (WHO) last year linked to causing cancer... (Source: NaturalNews.com)
Source: NaturalNews.com - July 13, 2016 Category: Consumer Health News Source Type: news

What Are The Most Common Pediatric Cancers?
Discussion Cancer occurs in all ages including children. Fortunately cancer is much less common in the pediatric age group accounting for
Source: PediatricEducation.org - July 4, 2016 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

When Parents Get Cancer, Children Are Often The Forgotten Victims
On the first day of spring 2007, Francesca Giessmann, 43, a marketing executive and holistic health coach from Kirkland, Washington, was rushed to the emergency room with severe stomach pain. After running numerous tests, doctors gave her the diagnosis of stage 3 non-Hodgkin lymphoma. Shocked and saddened by the news of her cancer, Giessmann's thoughts quickly turned to her son, Leo, who'd turned 3 years old the month prior. "Leo was very young and could not fully understand what was going on," Giessmann said. "Our pediatrician suggested we try to keep everything normal. I spent a great deal of time in be...
Source: Healthy Living - The Huffington Post - June 30, 2016 Category: Consumer Health News Source Type: news

Popular weed killer faces lawsuit over cancer claims
Woman who used "Roundup" backpack sprayer once a week among dozens of people alleging the product caused non-Hodgkin's Lymphoma cancer (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - June 29, 2016 Category: Consumer Health News Source Type: news

Roche’s Gazyva/Gazyvaro showed superior progression-free survival compared to MabThera/Rituxan in people with previously untreated follicular lymphoma
Roche today announced positive results from the pivotal phase III GALLIUM study in people with previously untreated follicular lymphoma, the most common type of indolent (slow-growing) non-Hodgkin lymphoma (iNHL). (Source: Roche Media News)
Source: Roche Media News - May 27, 2016 Category: Pharmaceuticals Source Type: news

Roche’s Gazyva/Gazyvaro showed superior progression-free survival compared to MabThera/Rituxan in people with previously untreated follicular lymphoma
Roche today announced positive results from the pivotal phase III GALLIUM study in people with previously untreated follicular lymphoma, the most common type of indolent (slow-growing) non-Hodgkin lymphoma (iNHL). (Source: Roche Investor Update)
Source: Roche Investor Update - May 27, 2016 Category: Pharmaceuticals Source Type: news

Monsanto now facing wave of chemical negligence lawsuits over glyphosate (Roundup) and cancer deaths
(NaturalNews) Teri McCall, the widow of a prominent farmer from Cambria, California, has just filed a wrongful death lawsuit against Monsanto Co. Anthony Jackson 'Jack' McCall, 69, died December 26, of terminal non-Hodgkin's lymphoma, after using Roundup weed killer on his 20-acre... (Source: NaturalNews.com)
Source: NaturalNews.com - May 20, 2016 Category: Consumer Health News Source Type: news

How Activists Are Restricting Use of a Major Pesticide
Glyphosate, the world’s most widely-used herbicide, has become a major target for environmentalists. But despite growing evidence of the chemical’s potentially dangerous health effects—the pesticide was deemed a “probable human carcinogen” by the World Health Organization last year—efforts to ban the chemical in the U.S. have repeatedly failed. Supporters of glyphosate, which is often used together with genetically modified crops, respond that no study has proven that the chemical definitively causes cancer in humans, and note that the pesticide effectively protects crops that feed milli...
Source: TIME.com: Top Science and Health Stories - May 17, 2016 Category: Consumer Health News Authors: Justin Worland Tags: Uncategorized activists Agriculture Cancer crops Environment Farming glyphosate hawaii Roundup toxins Source Type: news

Occupation and Risk of Non-Hodgkin Lymphoma and Its SubtypesOccupation and Risk of Non-Hodgkin Lymphoma and Its Subtypes
Do specific occupations confer a higher risk of developing non-Hodgkin lymphoma? Environmental Health Perspectives (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 10, 2016 Category: Consumer Health News Tags: Public Health & Prevention Journal Article Source Type: news

People with hepatitis C are two to five times more likely to develop certain head and neck cancers
(University of Texas M. D. Anderson Cancer Center) Long associated with liver cancer and non-Hodgkin's lymphoma, a study from The University of Texas MD Anderson Cancer Center reveals for the first time that the hepatitis C virus is associated with certain head and neck cancers. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 13, 2016 Category: Global & Universal Source Type: news

PET obviates toxic chemo for some Hodgkin's patients
By using FDG-PET to guide chemotherapy, oncologists can significantly increase...Read more on AuntMinnie.comRelated Reading: Cancer mortality continues to drop in U.S. SNMMI: PET/CT aids non-Hodgkin's lymphoma patients NEJM: PET for Hodgkin's lymphoma prevents unnecessary radiotherapy FDG-PET finds bone marrow involvement in Hodgkin's lymphoma FDG-PET predicts event-free survival in Hodgkin's lymphoma (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - April 12, 2016 Category: Radiology Source Type: news

Glyphosate: Claims against Monsanto for 'Farmer's Cancer'
Studies of occupational exposure to Glyphosate report increased risks for non-Hodgkin Lymphoma, Multiple Myeloma, Hairy Cell Leukemia, and Chronic Lymphocytic Leukemia (Source: Disabled World)
Source: Disabled World - March 17, 2016 Category: Disability Tags: Warnings - Alerts & Advisories Source Type: news

Gilead Stops Six Trials Due to Adverse Events, Death
The six clinical trials in question involved small lymphocytic lymphoma, CLL, and indolent non-Hodgkin lymphoma (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - March 16, 2016 Category: Pharmaceuticals Source Type: news

ADC Therapeutics begins dosing in ADCT-402 Phase I trial for B-NHL patients
Swiss firm ADC Therapeutics (ADCT) has started a Phase I trial of its antibody drug conjugate (ADC) ADCT-402 in patients with relapsed or refractory B-cell non-Hodgkin Lymphoma (B-NHL). (Source: Drug Development Technology)
Source: Drug Development Technology - March 14, 2016 Category: Pharmaceuticals Source Type: news

Did an artificial football pitch cause this amateur player's death?
Ian Cole, from Basingstoke, Hampshire, died in 2012 of non-Hodgkin lymphoma, an illness which has caused the deaths of more than 100 footballers in America in recent years. (Source: the Mail online | Health)
Source: the Mail online | Health - March 9, 2016 Category: Consumer Health News Source Type: news

Seattle Genetics begins Phase I trial of SGN-CD19B to treat non-Hodgkin lymphoma
Seattle Genetics has started a Phase I clinical trial of SGN-CD19B, a new antibody-drug conjugate (ADC) for relapsed or refractory patients with B-cell non-Hodgkin lymphoma (NHL). (Source: Drug Development Technology)
Source: Drug Development Technology - February 26, 2016 Category: Pharmaceuticals Source Type: news

Medical News Today: Is height, weight linked to rise in non-Hodgkin's lymphoma?
Non-Hodgkin's lymphoma has been on the rise for the last 30 years. The reasons for this are unclear, but investigations into height and weight are yielding fresh clues. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 22, 2016 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news

Weight and height during adolescence may impact future risk of developing Non-Hodgkin's lymphoma
(Wiley) A new analysis indicates that higher body weight and taller stature during adolescence increase the risk of developing Non-Hodgkin's lymphoma, a type of cancer of the lymphatic system. The findings are published early online in CANCER, a peer-reviewed journal of the American Cancer Society. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 22, 2016 Category: Cancer & Oncology Source Type: news

New Cancer Therapy Could Give Hope To 'Incurable' Patients
A new experimental treatment has achieved what chemotherapy and bone marrow transplants have failed to do: put chronic, relapsing blood cancers into remission. What's more, it uses the body's own natural defense system to attack these cancerous growths.  The treatment involves T cells, a type of immune cell that works as your body's own personal S.W.A.T. team to detect, surround, and destroy foreign invaders like bacteria or viruses. Historically, cancerous cells have grown too fast for T cells to mount an effective defense, and they can also trick T cells into thinking that they’re a healthy part of t...
Source: Science - The Huffington Post - February 17, 2016 Category: Science Source Type: news

FDA to Start Testing for Glyphosate in Food
This article originally appeared on Civil Eats (Source: TIME.com: Top Science and Health Stories)
Source: TIME.com: Top Science and Health Stories - February 17, 2016 Category: Consumer Health News Authors: Carey Gillam / CivilEats.com Tags: Uncategorized Cancer FDA Food glyphosate health Nutrition Pesticide public health Roundup Toxin toxins weed killer Source Type: news

Alzheimer's disease 'wonder drug' claims are premature
ConclusionThe number of people with Alzheimer's disease is increasing as the global population ages. Researchers have estimated 44 million people currently have the condition, and this number will grow to more than 135 million by 2050. It's believed the condition is caused at least in part by the accumulation of toxic aggregates of beta-amyloid protein pieces in the brain. Researchers hope stopping this aggregation could be a way to prevent or treat the disease, but have not yet found successful ways of doing this.This piece of research looked at nerve cells and microscopic worms genetically modified to develop beta-amyloi...
Source: NHS News Feed - February 15, 2016 Category: Consumer Health News Tags: Medication Neurology Older people Source Type: news

The Cancer Moonshot Could Depend Most on You
In his State of the Union address, President Barack Obama announced that Vice President Joe Biden would lead an effort toward a "moonshot" cure for cancer. More recently, Vice President Biden met with health care leaders at the World Economic Forum in Davos to build momentum for the initiative, and later will meet with agency officials and Cabinet members about how the federal government can fund more research and treatment. This is an ambitious task, to say the least, especially for a disease whose "cure" is often regarded as synonymous with an impossible dream. Cancer kills more than half a milli...
Source: Science - The Huffington Post - February 8, 2016 Category: Science Source Type: news

NICE consulting on non-Hodgkin's lymphoma guideline
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - February 1, 2016 Category: Drugs & Pharmacology Source Type: news

Valor begins dosing in Phase I trial of IGN002 to treat non-Hodgkin lymphoma
Valor Biotherapeutics (Valor) has started a Phase I clinical trial of its lead product candidate, IGN002, to treat patients with refractory and relapsed non-Hodgkin lymphoma (NHL). (Source: Drug Development Technology)
Source: Drug Development Technology - January 11, 2016 Category: Pharmaceuticals Source Type: news

New data from pivotal study showed Roche’s Gazyva/Gazyvaro induced deep remissions and provided meaningful quality of life improvements in people with difficult-to-treat indolent non-Hodgkin lymphoma
Roche today announced follow-up results from the pivotal phase III GADOLIN study in people with indolent non-Hodgkin lymphoma (iNHL) who relapsed during or within six months after treatment with a MabThera®/Rituxan® (rituximab)-based regimen. (Source: Roche Media News)
Source: Roche Media News - December 7, 2015 Category: Pharmaceuticals Source Type: news

New data from pivotal study showed Roche’s Gazyva/Gazyvaro induced deep remissions and provided meaningful quality of life improvements in people with difficult-to-treat indolent non-Hodgkin lymphoma
Roche today announced follow-up results from the pivotal phase III GADOLIN study in people with indolent non-Hodgkin lymphoma (iNHL) who relapsed during or within six months after treatment with a MabThera®/Rituxan® (rituximab)-based regimen. (Source: Roche Investor Update)
Source: Roche Investor Update - December 7, 2015 Category: Pharmaceuticals Source Type: news

Amgen and Merck Announce Cancer Immunotherapy Collaboration for Patients with Non-Hodgkin Lymphoma
Dateline City: THOUSAND OAKS, Calif. and KENILWORTH, N.J. Collaboration Includes Additional Select Advanced Solid Tumors THOUSAND OAKS, Calif. and KENILWORTH, N.J. – Amgen (NASDAQ:AMGN) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced a cancer immunotherapy collaboration to support a Phase 1b/3 study investigating BLINCYTO® (blinatumomab) in combination with KEYTRUDA® (pembrolizumab) in patients with diffuse large B-cell lymphoma (DLBCL), which is the most common type of non-Hodgkin lymphoma (NHL). BLINCYTO...
Source: Merck - December 4, 2015 Category: Pharmaceuticals Source Type: news

9/11 First Responders Fight for Health Care Extension
WASHINGTON (AP) — A day after undergoing chemotherapy, 9/11 first responder Robert Digiovanni stood angrily outside Senate Majority Leader Mitch McConnell's office, railing about politics interfering with life-or-death issues. Digiovanni, who has non-Hodgkin lymphoma, had been lobbying for legislation to extend expired health care benefits for himself and others who were exposed to toxic dust after the 2001 attacks in New York. But the extension wasn't included in a massive transportation bill released this week, as some expected, and Digiovanni and his fellow firefighters blamed the Republican leader. "I am v...
Source: JEMS Administration and Leadership - December 3, 2015 Category: Emergency Medicine Tags: News Administration and Leadership General News History of EMS Provider Wellness & Safety Source Type: news

9/11 First Responders Fight for Health Care Extension
WASHINGTON (AP) — A day after undergoing chemotherapy, 9/11 first responder Robert Digiovanni stood angrily outside Senate Majority Leader Mitch McConnell's office, railing about politics interfering with life-or-death issues. Digiovanni, who has non-Hodgkin lymphoma, had been lobbying for legislation to extend expired health care benefits for himself and others who were exposed to toxic dust after the 2001 attacks in New York. But the extension wasn't included in a massive transportation bill released this week, as some expected, and Digiovanni and his fellow firefighters blamed the Republican leader. "I am v...
Source: JEMS Operations - December 3, 2015 Category: Emergency Medicine Tags: News Administration and Leadership General News History of EMS Provider Wellness & Safety Source Type: news

9/11 First Responders Fight for Health Care Extension
WASHINGTON (AP) — A day after undergoing chemotherapy, 9/11 first responder Robert Digiovanni stood angrily outside Senate Majority Leader Mitch McConnell's office, railing about politics interfering with life-or-death issues. Digiovanni, who has non-Hodgkin lymphoma, had been lobbying for legislation to extend expired health care benefits for himself and others who were exposed to toxic dust after the 2001 attacks in New York. But the extension wasn't included in a massive transportation bill released this week, as some expected, and Digiovanni and his fellow firefighters blamed the Republican leader. "I am v...
Source: JEMS Special Topics - December 3, 2015 Category: Emergency Medicine Tags: News Administration and Leadership General News History of EMS Provider Wellness & Safety Source Type: news

9/11 First Responders Fight for Health Care Extension
WASHINGTON (AP) — A day after undergoing chemotherapy, 9/11 first responder Robert Digiovanni stood angrily outside Senate Majority Leader Mitch McConnell's office, railing about politics interfering with life-or-death issues. Digiovanni, who has non-Hodgkin lymphoma, had been lobbying for legislation to extend expired health care benefits for himself and others who were exposed to toxic dust after the 2001 attacks in New York. But the extension wasn't included in a massive transportation bill released this week, as some expected, and Digiovanni and his fellow firefighters blamed the Republican leader. "I ...
Source: JEMS Special Topics - December 3, 2015 Category: Emergency Medicine Tags: News Administration and Leadership Source Type: news

Kidney failure and its treatment may impact cancer risk
Risk of kidney and thyroid cancers was especially high when kidney failure patients were on dialysis, researchers have discovered. Conversely, risk of non-Hodgkin lymphoma, melanoma, lung cancer, and certain skin cancers was highest following kidney transplantation, likely due to immunosuppressant medications. Kidney failure is on the rise and currently afflicts an estimated 2 million people worldwide. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - November 13, 2015 Category: Science Source Type: news